Surgery may extend life in men with early bone metastases, major trial tests

This study looks at whether removing the prostate and nearby lymph nodes, in addition to standard drug therapy, helps men with prostate cancer that has spread to a few bones live longer and delay the cancer becoming resistant to treatment. About 452 men with intermediate- or high-risk prostate cancer and limited bone metastases are being followed for up to 10 years. The goal is to see if the combination approach improves cancer-specific survival and quality of life compared to drug therapy alone.